Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2026-08-24 17:21:48 ET · period of report 2026-08-24 · accession 0001628280-26-058684 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-08-24 17:21 | 2026-08-24 | ABCL | Hayden Michael R | Dir | P - Purchase | $10.64 | +53.6K | 1.37M | +4% | +$570.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-08-24 | P | A | 53,613 | $10.64 | 1,373,397 | I See footnote | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. (F2) These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. |